XML 50 R40.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized $ 2,739 $ 25,364
AstraZeneca Agreements [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized 36,900 27,100
Drug Product Revenue, Net [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized 2,595 24,486
Drug Product Revenue, Net [Member] | Astellas Agreement [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized 2,600 (1,200)
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Japan [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized 1,781 (2,205)
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Europe [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized 814 1,021
Drug Product Revenue, Net [Member] | AstraZeneca Agreements [Member] | U.S. [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized $ 0 $ 25,670